Results 71 to 80 of about 4,448 (207)
Journal of Hospital Medicine, Volume 21, Issue 2, Page 200-204, February 2026.
Gurpreet Dhaliwal +4 more
wiley +1 more source
Clinical Case Reports, Volume 13, Issue 11, November 2025.ABSTRACT The purpose of this case report is to highlight anticoagulation management of phlegmasia cerulea dolens, particularly in a patient with a recent ischemic stroke that underwent hemorrhagic transformation. In select cases, delayed anticoagulation after appropriate neurological clearance can be a viable approach to prevent thrombotic progression ...
Reem Sarsour +4 more
wiley +1 more source
Acta Medica Indonesiana, 2022 Antiphospholipid syndrome (APLS) is an autoimmune condition which commonly manifests as an arterial or venous thrombosis affecting medium to large vessels, with the presence of antiphospholipid antibodies.
Rathika Rajah, Rizna A Cader
doaj +2 more sources
Clinical Case Reports, Volume 13, Issue 11, November 2025.ABSTRACT Thrombocytopenia (TCP) is a well‐known contraindication for thrombolytic therapy due to the associated risk of bleeding. This report discusses a 34‐year‐old woman presented with massive pulmonary embolism (PE) and severe TCP. She was treated with systemic thrombolysis (ST), and fortunately, a good therapeutic response was achieved without ...
Arman Ahmadzadeh +5 more
wiley +1 more source
LUNGS IN ANTIPHOSPHOLIPID SYNDROME – THREE CASE REPORTS
Zdravniški Vestnik, 2001 Background. Three patients with antiphospholipid syndrome and lung involvement are presented. Except in one case, lung pathology was caused most probably by thrombotic and thrombembolic events in the lung circulation due to antiphospholipid syndrome.
Zlata Remškar
doaj
ACR Open Rheumatology, Volume 7, Issue 10, October 2025.Objective Antiphospholipid antibody (aPL) syndrome (APS) classification requires a thrombotic event and detection of lupus anticoagulant (LAC), anticardiolipin antibodies (aCL), or anti–β2‐glycoprotein I (anti‐β2GPI) antibodies on two occasions ≥12 weeks apart. Here, we investigated the utility of anti–phosphatidylserine/prothrombin complex (anti‐PS/PT)
Christina Donath +4 more
wiley +1 more source
Journal of Clinical Apheresis, Volume 40, Issue 5, October 2025.ABSTRACT Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL), macro‐ and micro‐vascular thromboembolic complications. Lupus anticoagulant‐hypoprothrombinemia (LAHPS) may confound the diagnosis and management of bleeding. Catastrophic APS has a category 1 indication for therapeutic plasma exchange (TPE).
Joshua Nicholas +4 more
wiley +1 more source
La Sindrome Antifosfolipidi: revisione critica degli attuali aspetti diagnostici, patogenetici e terapeutici [PDF]
, 2012 La sindrome antifosfolipidi (aPS) identifica una condizione ad aumentato rischio di occlusione vascolare e/o complicanze gravidiche, la cui definizione è stata stabilita nel 2005 sulla base di un consenso internazionale.
PARENTI, MADDALENA
core
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil [PDF]
, 2011 To discuss and share knowledge around advances in the care of patients with thrombotic disorders, the Third International Symposium of Thrombosis and Anticoagulation was held in So Paulo, Brazil, from October 14-16, 2010.
Alexander, John H. +26 more
core +1 more source
Post‐Viral Acquired Idiopathic Purpura Fulminans Caused by Anti‐Protein S Antibodies
Acta Paediatrica, Volume 114, Issue 10, Page 2511-2517, October 2025.ABSTRACT Acquired Idiopathic purpura fulminans is a rare pathology caused by anti‐protein S antibodies. We have conducted a literature review focusing on the most recent developments in diagnosis and management. Diagnosis is based on the demonstration of typical necrotic purpura lesions on the legs. Treatment must be initiated without delay by infusion
Alexandre Theron +2 more
wiley +1 more source